119 related articles for article (PubMed ID: 19684616)
1. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage.
Yuan BZ; Chapman J; Reynolds SH
Oncogene; 2009 Oct; 28(43):3775-86. PubMed ID: 19684616
[TBL] [Abstract][Full Text] [Related]
2. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
3. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
4. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
5. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.
Zhou W; Hu J; Tang H; Wang D; Huang X; He C; Zhu H
BMC Cancer; 2011 Nov; 11():485. PubMed ID: 22078414
[TBL] [Abstract][Full Text] [Related]
7. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells.
Kabore AF; Sun J; Hu X; McCrea K; Johnston JB; Gibson SB
Apoptosis; 2006 Jul; 11(7):1175-93. PubMed ID: 16699949
[TBL] [Abstract][Full Text] [Related]
8. Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines.
Naumann K; Schmich K; Jaeger C; Kratz F; Merfort I
Anticancer Drugs; 2012 Jul; 23(6):614-26. PubMed ID: 22314265
[TBL] [Abstract][Full Text] [Related]
9. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460.
Voortman J; Checinska A; Giaccone G; Rodriguez JA; Kruyt FA
Mol Cancer Ther; 2007 Mar; 6(3):1046-53. PubMed ID: 17363497
[TBL] [Abstract][Full Text] [Related]
11. TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.
Yuan BZ; Chapman J; Ding M; Wang J; Jiang B; Rojanasakul Y; Reynolds SH
BMC Cancer; 2013 Mar; 13():140. PubMed ID: 23517112
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis.
Nencioni A; Hua F; Dillon CP; Yokoo R; Scheiermann C; Cardone MH; Barbieri E; Rocco I; Garuti A; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Blood; 2005 Apr; 105(8):3255-62. PubMed ID: 15613543
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.
Saulle E; Petronelli A; Pasquini L; Petrucci E; Mariani G; Biffoni M; Ferretti G; Scambia G; Benedetti-Panici P; Cognetti F; Humphreys R; Peschle C; Testa U
Apoptosis; 2007 Apr; 12(4):635-55. PubMed ID: 17252198
[TBL] [Abstract][Full Text] [Related]
14. Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin 1 are refractory to proteasome inhibitor-induced apoptosis.
Chen C; Lin H; Karanes C; Pettit GR; Chen BD
Cancer Res; 2000 Aug; 60(16):4377-85. PubMed ID: 10969781
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells.
Zhang XM; Lin H; Chen C; Chen BD
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):127-33. PubMed ID: 10229667
[TBL] [Abstract][Full Text] [Related]
16. Improved apoptotic cell death in drug-resistant non-small-cell lung cancer cells by tumor necrosis factor-related apoptosis-inducing ligand-based treatment.
Gatti L; Cossa G; Tinelli S; Carenini N; Arrighetti N; Pennati M; Cominetti D; De Cesare M; Zunino F; Zaffaroni N; Perego P
J Pharmacol Exp Ther; 2014 Mar; 348(3):360-71. PubMed ID: 24345465
[TBL] [Abstract][Full Text] [Related]
17. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC.
Ma J; Zhao Z; Wu K; Xu Z; Liu K
Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells.
He Q; Huang Y; Sheikh MS
Oncogene; 2004 Apr; 23(14):2554-8. PubMed ID: 14691451
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.
Hougardy BM; Maduro JH; van der Zee AG; de Groot DJ; van den Heuvel FA; de Vries EG; de Jong S
Int J Cancer; 2006 Apr; 118(8):1892-900. PubMed ID: 16287099
[TBL] [Abstract][Full Text] [Related]
20. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776
[No Abstract] [Full Text] [Related]
[Next] [New Search]
